OBJECTIVE: To determine whether APOE epsilon 4 predicts rate of cognitive change in incident and prevalent Alzheimer disease (AD). METHODS: Individuals were recruited from two longitudinal cohort studies-the Washington Heights and Inwood Columbia Aging Project (WHICAP; population-based) and the Predictors Study (clinic-based)--and were followed for an average of 4 years. Three samples of participants diagnosed with AD, with diverse demographic characteristics and baseline cognitive functioning, were studied: 1) 199 (48%) of the incident WHICAP cases; 2) 215 (54%) of the prevalent WHICAP cases; and 3) 156 (71%) of the individuals diagnosed with AD in the Predictors Study. Generalized estimating equations were used to test whether rate of cognitive change, measured using a composite cognitive score in WHICAP and the Mini-Mental State Examination in Predictors, varied as a function of epsilon 4 status in each sample. RESULTS: The presence of at least one epsilon 4 allele was associated with faster cognitive decline in the incident population-based AD group (p = 0.01). Parallel results were produced for the two prevalent dementia samples only when adjusting for disease severity or excluding the most impaired participants from the analyses. CONCLUSION: APOE epsilon 4 may influence rate of cognitive decline most significantly in the earliest stages of Alzheimer disease.
OBJECTIVE: To determine whether APOE epsilon 4 predicts rate of cognitive change in incident and prevalent Alzheimer disease (AD). METHODS: Individuals were recruited from two longitudinal cohort studies-the Washington Heights and Inwood Columbia Aging Project (WHICAP; population-based) and the Predictors Study (clinic-based)--and were followed for an average of 4 years. Three samples of participants diagnosed with AD, with diverse demographic characteristics and baseline cognitive functioning, were studied: 1) 199 (48%) of the incident WHICAP cases; 2) 215 (54%) of the prevalent WHICAP cases; and 3) 156 (71%) of the individuals diagnosed with AD in the Predictors Study. Generalized estimating equations were used to test whether rate of cognitive change, measured using a composite cognitive score in WHICAP and the Mini-Mental State Examination in Predictors, varied as a function of epsilon 4 status in each sample. RESULTS: The presence of at least one epsilon 4 allele was associated with faster cognitive decline in the incident population-based AD group (p = 0.01). Parallel results were produced for the two prevalent dementia samples only when adjusting for disease severity or excluding the most impaired participants from the analyses. CONCLUSION:APOE epsilon 4 may influence rate of cognitive decline most significantly in the earliest stages of Alzheimer disease.
Authors: M R Meyer; J T Tschanz; M C Norton; K A Welsh-Bohmer; D C Steffens; B W Wyse; J C Breitner Journal: Nat Genet Date: 1998-08 Impact factor: 38.330
Authors: Y Stern; J Brandt; M Albert; D M Jacobs; X Liu; K Bell; K Marder; M Sano; S Albert; C Del-Castillo Castenada; F Bylsma; B Tycko; R Mayeux Journal: Ann Neurol Date: 1997-05 Impact factor: 10.422
Authors: M Martinez; D Campion; A Brice; D Hannequin; B Dubois; O Didierjean; A Michon; C Thomas-Anterion; M Puel; T Frebourg; Y Agid; F Clerget-Darpoux Journal: Arch Neurol Date: 1998-06
Authors: M Lehtovirta; J Kuikka; S Helisalmi; P Hartikainen; A Mannermaa; M Ryynänen; H Soininen Journal: J Neurol Neurosurg Psychiatry Date: 1998-06 Impact factor: 10.154
Authors: S Craft; L Teri; S D Edland; W A Kukull; G Schellenberg; W C McCormick; J D Bowen; E B Larson Journal: Neurology Date: 1998-07 Impact factor: 9.910
Authors: Liana G Apostolova; Kristy S Hwang; John P Andrawis; Amity E Green; Sona Babakchanian; Jonathan H Morra; Jeffrey L Cummings; Arthur W Toga; John Q Trojanowski; Leslie M Shaw; Clifford R Jack; Ronald C Petersen; Paul S Aisen; William J Jagust; Robert A Koeppe; Chester A Mathis; Michael W Weiner; Paul M Thompson Journal: Neurobiol Aging Date: 2010-06-11 Impact factor: 4.673
Authors: D F Tate; E S Neeley; M C Norton; J T Tschanz; M J Miller; L Wolfson; C Hulette; C Leslie; K A Welsh-Bohmer; B Plassman; Erin D Bigler Journal: Brain Res Date: 2010-12-21 Impact factor: 3.252
Authors: S Barral; T Bird; A Goate; M R Farlow; R Diaz-Arrastia; D A Bennett; N Graff-Radford; B F Boeve; R A Sweet; Y Stern; R S Wilson; T Foroud; J Ott; R Mayeux Journal: Neurology Date: 2012-04-25 Impact factor: 9.910
Authors: M E Soto; S Andrieu; C Arbus; M Ceccaldi; P Couratier; T Dantoine; J-F Dartigues; S Gillette-Guyonnet; F Nourhashemi; P-J Ousset; M Poncet; F Portet; J Touchon; B Vellas Journal: J Nutr Health Aging Date: 2008-12 Impact factor: 4.075
Authors: Jon B Toledo; Xiao Da; Michael W Weiner; David A Wolk; Sharon X Xie; Steven E Arnold; Christos Davatzikos; Leslie M Shaw; John Q Trojanowski Journal: Acta Neuropathol Date: 2014-01-03 Impact factor: 17.088
Authors: Sarah E Monsell; Lilah M Besser; Katherine B Heller; Harvey Checkoway; Irene Litvan; Walter A Kukull Journal: Parkinsonism Relat Disord Date: 2014-02-13 Impact factor: 4.891